MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of common stock
$791,418
Net proceeds from
note payable...
$300,000
Net proceeds from
note payable...
$200,000
Net proceeds from
option exercises
$113,541
Net cash provided by
financing activities
$1,404,959
Net decrease in cash
$265,232
Canceled cashflow
$1,139,727
Deferred revenue
$1,275,000
Accounts payable
$216,893
Accrued expenses
$201,392
Prepaid expenses and
other current assets
-$103,676
Provision for credit
losses
$91,401
Stock-based compensation
$85,986
Depreciation expense
$85,463
Amortization of operating
lease right of use...
$71,476
Vendor expense settled
in shares of common...
$51,000
Provision for inventory
obsolescence
$19,371
Net cash used in
operating activities
-$864,971
Net cash used in
investing activities
-$274,756
Canceled cashflow
$2,201,658
Net loss
-$2,512,216
Purchases of property and
equipment
$274,756
Accounts receivable, net
$404,863
Inventory, net
$82,690
Operating lease
liabilities
-$66,860
Back
Back
Cash Flow
source: myfinsight.com
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)